The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
Yasuhiro Oki
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorHubert Chuang
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorBeth Chasen
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorAaron Jessop
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorTinsu Pan
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorMichelle Fanale
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorBouthaina Dabaja
Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorNathan Fowler
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorJorge Romaguera
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLuis Fayad
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorFredrick Hagemeister
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorMaria Alma Rodriguez
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorSattva Neelapu
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorFelipe Samaniego
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLarry Kwak
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorCorresponding Author
Anas Younes
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Correspondence: Anas Younes, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065, USA.
E-mail: [email protected]
Search for more papers by this authorYasuhiro Oki
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorHubert Chuang
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorBeth Chasen
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorAaron Jessop
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorTinsu Pan
Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorMichelle Fanale
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorBouthaina Dabaja
Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorNathan Fowler
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorJorge Romaguera
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLuis Fayad
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorFredrick Hagemeister
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorMaria Alma Rodriguez
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorSattva Neelapu
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorFelipe Samaniego
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorLarry Kwak
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Search for more papers by this authorCorresponding Author
Anas Younes
Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Correspondence: Anas Younes, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065, USA.
E-mail: [email protected]
Search for more papers by this authorSummary
The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.
Supporting Information
| Filename | Description |
|---|---|
| bjh12715-sup-0001-TableS1.docxWord document, 23.1 KB | Table S1. Prognostic impact of each characteristic in advanced disease on progression free survival by univariate analysis using Cox proportional hazard model. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M.S. & Barrington, S.F. (2013) International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. Journal of Nuclear Medicine, 54, 683–690.
- Cerci, J.J., Pracchia, L.F., Linardi, C.C., Pitella, F.A., Delbeke, D., Izaki, M., Trindade, E., Soares, J. Jr, Buccheri, V. & Meneghetti, J.C. (2010) 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. Journal of Nuclear Medicine, 51, 1337–1343.
- Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746–3752.
- Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.M., Berthelsen, A.K. & Specht, L. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, 52–59.
- Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A. & Cheson, B.D. & Imaging Subcommittee of International Harmonization Project in, L. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology, 25, 571–578.
- Le Roux, P.Y., Gastinne, T., Le Gouill, S., Nowak, E., Bodet-Milin, C., Querellou, S., Mahe, B., Dubruille, V., Blin, N., Salaun, P.Y. & Bodere-Kraeber, F. (2011) Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. European Journal of Nuclear Medicine and Molecular Imaging, 38, 1064–1071.
- Matloub, Y., Lindemulder, S., Gaynon, P.S., Sather, H., La, M., Broxson, E., Yanofsky, R., Hutchinson, R., Heerema, N.A., Nachman, J., Blake, M., Wells, L.M., Sorrell, A.D., Masterson, M., Kelleher, J.F. & Stork, L.C. (2006) Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood, 108, 1165–1173.
- Meignan, M., Gallamini, A., Meignan, M., Gallamini, A. & Haioun, C. (2009) Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leukaemia & Lymphoma, 50, 1257–1260.
- Press, O.W., LeBlanc, M., Rimsza, L.M., Schoder, H., Friedberg, J.W., Evens, A.M., Li, H., Bartlett, N.L., LaCasce, A.S., Sweetenham, J.W., Straus, D.J., Noy, A., Kostakoglul, L., Grewal, R.K., Hsi, E.D., Gascoyne, R.D., Cheson, B.D., Kahl, B.S., Miller, T.P. & Fisher, R.I. (2013) A phase II trial of response-adapted therapy of stages III-IV Hodgkin lymphoma using early interim FDG-PET imaging: US Intergroup S0816. Hematological Oncology, 31 (Suppl 1), abstr 124.
- Terasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T. & Nagai, H. (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. Journal of Clinical Oncology, 27, 1906–1914.
- Zinzani, P.L., Rigacci, L., Stefoni, V., Broccoli, A., Puccini, B., Castagnoli, A., Vaggelli, L., Zanoni, L., Argnani, L., Baccarani, M. & Fanti, S. (2012) Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. European Journal of Nuclear Medicine and Molecular Imaging, 39, 4–12.
Citing Literature
